Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.
about
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivinEstrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cellsMechanisms of bone metastases of breast cancerAfrican ancestry and higher prevalence of triple-negative breast cancer: findings from an international studyCancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerApplication of metabolomics in drug resistant breast cancer researchPreventing breast cancer in LMICs via screening and/or early detection: The real and the surrealEstrogen-Related Receptors in Breast Cancer and Prostate CancerFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatmentsHuman epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.ERbeta in breast cancer--onlooker, passive player, or active protector?Age-related crossover in breast cancer incidence rates between black and white ethnic groups.Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin.Effect of 6-months of physical exercise on the nitrate/nitrite levels in hypertensive postmenopausal womenParallel routes of human carcinoma development: implications of the age-specific incidence dataFunctional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Δ(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ)Urban-Rural Variations in Quality-of-Life in Breast Cancer Survivors Prescribed Endocrine Therapy.Assessment of fracture risk in women with breast cancer using current vs emerging guidelines.Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.Epidemiology of inflammatory breast cancer (IBC).B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cellsFamilial relative risks for breast cancer by pathological subtype: a population-based cohort studyConsiderations for payers in managing hormone receptor-positive advanced breast cancer.Distinct breast cancer subtypes in women with early-onset disease across racesModification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studiesIncorporating tumour pathology information into breast cancer risk prediction algorithms.Adjuvant Endocrine Therapy in Premenopausal PatientsHow many etiological subtypes of breast cancer: two, three, four, or more?Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapyBreast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapyA population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative.Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.Testing for HER2 in Breast Cancer: A Continuing Evolution.Temporal trend, clinicopathologic and sociodemographic characterization of age at diagnosis of breast cancer among US women diagnosed from 1990 to 2009
P2860
Q21195209-F6BBC6A1-1C06-45E8-8B71-DCD8EE74DD19Q24319134-8ACA0334-FC44-4084-8973-3FED5ACB08E4Q24597798-B1485B18-4B3C-4E27-B869-97178142631CQ24632274-38794437-7141-4EAA-8733-0BE38D7C93E1Q26743510-025A7E7F-6B3E-4597-BAD6-888AEC87153EQ26770482-0915559F-9C51-4EEC-A910-9E34A90390E3Q26866291-63D3A1A8-8EA8-4942-852D-A83FD0618DA2Q27027277-A43B8790-C38E-454C-AD84-DFF032EA36FAQ28084030-574081D3-A14C-45BE-A516-725E94BEE449Q28084982-D8B1095F-57FD-49B3-A786-E37C287C68BAQ28085004-1179E827-E782-447A-BCB1-5E6D076A5F86Q28477774-262A0E16-F741-439D-A4ED-C830248D602AQ30437453-66C85C72-6006-4E57-B576-4714C0F8055BQ30438399-09CC7485-F472-4754-B129-ABD37B2478D1Q30485944-6B285243-96FA-4DD9-9C46-DEE91BB4E705Q30841338-B13808E8-A835-4552-B613-B0C9B0DAD7BFQ33471782-5BC2BA63-5ADC-44DB-8A44-4838FD56A90FQ33506089-F58E2F41-F03E-4CD1-BD0D-C9DF359F7A82Q33584258-E8FC9524-6B6F-45FC-B7B0-EFD8C10C382BQ33601161-6F6474F7-0FE8-4795-ABB8-0776A3F15C2DQ33616178-E82FEE36-8A04-4D0E-9A80-022D1F78D514Q33723674-12AC6FBD-9047-4F75-93AA-87FA42D2EFC1Q33751139-DDF41E84-7137-40B8-AF5F-3431B42D692DQ33781315-C3F623DF-70AA-4628-AC25-80C10BBC8327Q33786387-82B2FEA9-3D33-4F92-8A88-C1ACC77B4347Q33892928-EFF9E5C3-7EBA-45A0-ACF1-8D11B884810CQ33895422-C80477BA-4721-4435-885C-2E02E5099DC1Q33932660-7F9E5E06-CA9B-42E5-A167-571EB28AC882Q33957073-D2074C77-1A18-4608-8712-8E3066C6C631Q34048046-684D0B8B-3133-4852-8C10-BAEADA8B508AQ34096277-A2C1DF07-876B-4154-8AFF-5F18A8AFE1FFQ34106175-47CABBA5-DB3D-4806-A1AF-9EF0D1F8BD6FQ34250220-23903394-BB03-4329-8738-4CD48BE4FAB4Q34286594-24565B6C-6257-4CDD-9032-84A28ADC0727Q34315367-DC879002-C3D6-4F17-BADA-DBA162D6FCFCQ34341656-E55A9496-68CD-4462-9810-E2C83940CA5CQ34352887-EDD57628-3082-4A16-8605-A9FE9C6986D7Q34380520-375A9104-B9B3-4BF4-8A25-7ACE26C4BC91Q34424285-19A68ED9-9649-4846-80DB-5711FF83E965Q34484209-349D6EAA-9987-4ED4-A809-5140034DC4EE
P2860
Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Estrogen receptor breast cance ...... ogy, and End Results database.
@en
Estrogen receptor breast cance ...... ogy, and End Results database.
@nl
type
label
Estrogen receptor breast cance ...... ogy, and End Results database.
@en
Estrogen receptor breast cance ...... ogy, and End Results database.
@nl
prefLabel
Estrogen receptor breast cance ...... ogy, and End Results database.
@en
Estrogen receptor breast cance ...... ogy, and End Results database.
@nl
P2093
P2860
P356
P1476
Estrogen receptor breast cance ...... ogy, and End Results database.
@en
P2093
Otis W Brawley
William B Ershler
William F Anderson
P2860
P2888
P356
10.1023/A:1020299707510
P407
P577
2002-11-01T00:00:00Z
P6179
1036259989